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Introduction {#sec005}
============

Celiac disease (CD) is an immune-mediated systemic disorder triggered by gluten that occurs in genetically susceptible individuals \[[@pone.0212329.ref001], [@pone.0212329.ref002]\]. CD is characterized histologically by small intestinal mucosal damage, clinically by various intestinal and extraintestinal manifestations.

The presence of HLA-DQ2 or DQ8 is essential in the disease pathogenesis. T-lymphocytes recognize gliadin peptides presented by antigen presenting cells expressing DQ2 or DQ8 on cell surface, exclusively. Therefore, theoretically, either haplotype must be present in all CD-patients \[[@pone.0212329.ref003]\].

HLA-DQ2 is present in up to 90--95% of celiac cases. The HLA-DQ2 heterodimer consists of an α and a β subunit encoded by HLA-DQA1\*05 and HLA-DQB1\*02 alleles on chromosome 6, respectively \[[@pone.0212329.ref003]\]. Alleles are located on the same chromosome in *cis* configuration (DR3/DQ2 haplotype) or separately on homologous chromosomes in *trans* configuration (DR5/DQ7 and DR5/DQ2 haplotypes) \[[@pone.0212329.ref003]\]. The two types of DQ2 heterodimers are DQ2.5 (DQA1\*0501/B1\*0201) and DQ2.2 (DQA1\*0201/B1\*0202). Patients with heterodimers of DQ2.5 carry a high risk and with heterodimers of DQ2.2 carry a low risk of CD \[[@pone.0212329.ref002], [@pone.0212329.ref004], [@pone.0212329.ref005]\]. DQ2.2 molecules are structurally similar to DQ2.5, but the latter's gluten peptide-binding properties are less prominent \[[@pone.0212329.ref003], [@pone.0212329.ref004], [@pone.0212329.ref006]\]. Those with DQ2.2 haplotype are at high risk of CD but only if they are DQ2.2/2.5 or DQ2.2/DQ7 heterozygotes. In the latter case, functional DQ2.5 molecules can be assembled from α and β chains encoded separately on different chromosomes (DQA1\*0505 and DQB1\*0202, respectively); this constitution is called 'DQ2 in trans' \[[@pone.0212329.ref002], [@pone.0212329.ref005], [@pone.0212329.ref007], [@pone.0212329.ref008]\]. HLA-DQ8 is found up to 5--10% of CD patients, whose α and β chains are encoded by HLA-DQA1\*0301 and HLA-DQB1\*0302, respectively (that is, DR4/DQ8 haplotype with DR4-linked inheritance). A small minority of patients have half of the DQ2 heterodimer (either DQA\*05 or DQB\*02); however, it seems to be sufficient for effective antigen presentation \[[@pone.0212329.ref002], [@pone.0212329.ref005], [@pone.0212329.ref008]\].

Since the DQ2 molecule plays a crucial role in CD pathogenesis, the number of HLA DQB1\*0201 copies might have important consequences in CD patients: 4 αβ-chain combinations can be synthesized in heterozygotes but all HLA-DQ molecules are identical in homozygotes \[[@pone.0212329.ref005], [@pone.0212329.ref009], [@pone.0212329.ref010]\]. Experimental data support this connection: HLA-DQ2.5 homozygotes can present gluten peptides on antigen-presenting cells more effectively than HLA-DQ2.5 heterozygotes \[[@pone.0212329.ref004], [@pone.0212329.ref005]\]. HLA-DQ2.5 homozygotes are at fivefold risk of CD as compared to HLA-DQ2.5 heterozygotes \[[@pone.0212329.ref006], [@pone.0212329.ref009]--[@pone.0212329.ref011]\]. The presence of a second β chain seems decisive in determining the risk, whereas the role of a second α chain appears less important \[[@pone.0212329.ref010], [@pone.0212329.ref012], [@pone.0212329.ref013]\]. The magnitude of immune response depends on gene dose: HLA-DQ2.5 homozygotes show maximal T-cell activation and proinflammatory response, whereas heterozygotes exhibit less prominent responses. The more DQ2.5 molecules are expressed on antigen presenting cells, the stronger the immune activation is \[[@pone.0212329.ref004]--[@pone.0212329.ref006]\]. Based on these *in vitro* immunological studies, one might assume that HLA-DQ2 homozygosity alters the course of CD; furthermore, the gene dose effect is manifested *clinically* with an increased risk of complications \[[@pone.0212329.ref014]\].

To our best knowledge, no meta-analyses have been conducted on the clinical effects of HLA-DQB1\*02 gene dose in CD. It is assumed that patients with a double dose of HLA-DQB1\*02 exhibit worse clinical outcomes, though some papers reported on how HLA-DQ2 gene dose (i.e., the number of DQB1\*02 alleles) is associated with CD phenotype. This meta-analysis aims to investigate the association between HLA-DQB1\*02 gene dose and the disease characteristics.

Materials and methods {#sec006}
=====================

We conducted our meta-analysis observing the rules of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement ([S1 Appendix](#pone.0212329.s012){ref-type="supplementary-material"}) \[[@pone.0212329.ref015]\].

Search {#sec007}
------

PubMed (MEDLINE), Embase, Cochrane Controlled Register of Trials (CENTRAL), Web of Science, WHO Global Health Library, ClinicalTrials.gov, and Scopus were searched for articles discussing gene dose effect from inception until 22^nd^ October 2018. Our query was "celiac AND (homozyg\* OR heterozyg\* OR \"gene dose\" OR \"gene dosage\" OR \"double dose\" OR \"double dosage\" OR \"single dose\" OR \"single dosage\" OR \"zero dose\" OR \"zero dosage\" OR DQB1 OR DQ2.5 OR DQ2.2 OR DQ7 OR DQ8 OR \"DQ2 in trans\")". Reference lists and citing articles of the relevant studies were hand-searched for further papers. No filters were imposed upon the search. Draft of search in Embase is presented in [S2 Appendix](#pone.0212329.s013){ref-type="supplementary-material"}.

Our PICO format was, as follows: (P) celiac disease, (I~1~) zero-dose HLA-DQB1\*02, (I~2~) single-dose HLA-DQB1\*02, (C) double-dose HLA-DQB1\*02, (O) celiac phenotype at diagnosis including histological severity (atrophic vs. non-atrophic and Marsh 3c vs. Marsh 3a-b), clinical presentation (classical vs. non-classical and diarrhea vs. non-diarrhea), age at onset and at diagnosis, celiac-specific serology; concomitant immune-mediated disorders, dermatitis herpetiformis, anemia, dental complications, and malignant tumors.

Eligibility, selection, and data extraction {#sec008}
-------------------------------------------

We included original papers and conference abstracts, with the exclusion of case reports; and excluded comments, letters, editorials, and review articles. Eligible study design included both observational and experimental studies with adequate description of the genetic background and disease characteristics.

Eligible studies discussed celiac patients diagnosed in accordance with the current guidelines with known gene dose of HLA-DQB1\*02 (double, single, and zero doses) and reported at least one of our predefined outcomes of patients by genotypes, separately. On inclusion, only PCR-based HLA-typing (sequence-specific primer or oligonucleotide probes) was acceptable.

Outcomes included clinical presentation dichotomized into classical and non-classical phenotype according to the Oslo criteria. Classical and non-classical CD are defined by the presence and absence of signs and symptoms of malabsorption (i.e., diarrhea, steatorrhea, weight loss, or growth failure), respectively \[[@pone.0212329.ref016]\], or into groups with and without diarrhea. Age at diagnosis and at disease onset were assessed separately. On one hand, diagnostic histology was divided into atrophic (Marsh 3 grade) and non-atrophic (Marsh 0--2 grades) mucosal damage \[[@pone.0212329.ref017]\]. On the other hand, we analyzed the severity of villous atrophy graded by the Marsh-Oberhuber classification (Marsh 3c vs. Marsh 3a-b) \[[@pone.0212329.ref018]\]. Tissue transglutaminase antibodies and endomysial antibodies were in the focus when discussing diagnostic serology. Other outcomes included disease complications and comorbid conditions (i.e., anemia, osteoporosis, autoimmunity, dental complications, dermatitis herpetiformis, malignant tumors, and type 1 diabetes mellitus).

We combined the yield of search in a reference manager software (EndNote X7.4, Clarivate Analytics, Philadelphia, PA, US), followed by the removal of overlaps between database content and duplicate records. The duplicate-free pool was searched first by title, then by abstracts, and full-texts against our eligibility criteria. Each phase of selection was carried out by two independent review authors (PV and KS) in duplicate, discrepancies were resolved by third party (MS) arbitration. Investigators had no contact with the authors of the original papers.

The following data were collected by two investigators onto pre-constructed Excel sheets: publication data, study design, population (numbers and characteristics of participants), HLA-DQB1\*02 gene dose, age at onset; age, histology, serology, clinical presentation, anemia at diagnosis; concomitant immune-mediated disorders and complications: type 1 diabetes mellitus, dermatitis herpetiformis, dental enamel defect, recurrent aphthous stomatitis, enteropathy-associated T-cell lymphoma (EATL), small bowel carcinoma (SBC).

In the case of articles giving only HLA-DQ genotype, HLA-DQB1\*02 gene dose was calculated, as follows: double-dose---HLA-DQ2.5 homozygotes (DQ2.5/DQ2.5) and compound heterozygotes (DQ2.5/DQ2.2); single-dose---HLA-DQ2.5 heterozygotes (DQ2.5/DQX) and HLA-DQ2 in trans (DQ2.2/DQ7); and zero-dose---HLA-DQ8/DQX and HLA-DQ2.2/DQX, where X represents any alleles except for DQ2.5 \[[@pone.0212329.ref008], [@pone.0212329.ref019]--[@pone.0212329.ref028]\].

Risk of bias assessment {#sec009}
-----------------------

Two authors (MB and EP), unblinded to publication data, assessed the methodological quality of each study by using a tool developed *a priori* by our review team based on the Newcastle-Ottawa Scale ([S1 Table](#pone.0212329.s001){ref-type="supplementary-material"}). Results of risk of bias assessment were taken into account when assessing the limitations of the individual studies.

Statistical analysis {#sec010}
--------------------

A biostatistician (NF) carried out the statistical analysis by using Comprehensive Meta-Analysis software (Version 3, Biostat, Englewood, NJ). The random effect model with DerSimonian-Laird estimation was used for analysis \[[@pone.0212329.ref029]\]. For dichotomous outcomes (i.e., histology, clinical presentation, and diarrhea), we calculated odds ratios (ORs) and 95% confidence interval (CIs). For age at diagnosis, weighted mean difference (MD) and 95% CIs were calculated. Statistical significance was attained when *p*\<0.05.

Heterogeneity was tested with I^2^- and chi^2^-tests. An I^2^ of 0%-40%, 30%-60%, 50%-90%, and 75%-100% represented not important, moderate, substantial, and considerable between-study heterogeneity with *p*\<0.10 indicating statistical significance \[[@pone.0212329.ref030]\]. Since the clinical phenotype of CD diagnosed in childhood and adulthood may differ, we planned to set up study subgroups by age (children and adults) in each plot \[[@pone.0212329.ref031]--[@pone.0212329.ref035]\]. The number of studies was insufficient for meta-regression by gene dose.

Funnel plots were used to assess publication bias.

Sensitivity analysis was performed by omitting studies one-by-one from the analyses and recalculating the pooled effect.

Results {#sec011}
=======

Search and selection {#sec012}
--------------------

[Fig 1](#pone.0212329.g001){ref-type="fig"}. shows the flowchart of this work. Our search strategy yielded 6704 records (PubMed \[MEDLINE\]: 954, Embase: 2277, CENTRAL: 43, Web of Science: 925, WHO Global Health Library: 795, ClinicalTrials.gov: 6, and Scopus: 1704). Out of a total of 59 papers eligible for qualitative synthesis ([Table 1](#pone.0212329.t001){ref-type="table"} and [S2 Table](#pone.0212329.s002){ref-type="supplementary-material"}) \[[@pone.0212329.ref007], [@pone.0212329.ref008], [@pone.0212329.ref012]--[@pone.0212329.ref014], [@pone.0212329.ref019]--[@pone.0212329.ref028], [@pone.0212329.ref036]--[@pone.0212329.ref079]\], 24 were included in meta-analysis ([Table 1](#pone.0212329.t001){ref-type="table"}) \[[@pone.0212329.ref008], [@pone.0212329.ref012], [@pone.0212329.ref019]--[@pone.0212329.ref028], [@pone.0212329.ref036]--[@pone.0212329.ref047]\]. Results of meta-analysis are summarized in [Table 2](#pone.0212329.t002){ref-type="table"}, raw data on disease characteristics are presented in [S3 Table](#pone.0212329.s003){ref-type="supplementary-material"}.

![Flow chart of meta-analysis.](pone.0212329.g001){#pone.0212329.g001}

10.1371/journal.pone.0212329.t001

###### Characteristics of included studies.

![](pone.0212329.t001){#pone.0212329.t001g}

  Author (year)                                            Country           Settings                                        N^0^ of pts.                                     Age group                            Genotyping                                      
  -------------------------------------------------------- ----------------- ----------------------------------------------- ------------------------------------------------ ------------------------------------ ------------------ ---------------------------- ------------
  Akar et al. (2015) \[[@pone.0212329.ref036]\]            Turkey            prospective, single center, cross-sectional     36 CD pts                                        children                             PCR-SSP            HLA-DQB1\*0201 allele dose   5/24/7
  Araya et al. (2015) \[[@pone.0212329.ref019]\]           Chile             prospective, single center, case-control        56 CD pts and 166 first degree relatives         children and adults                  PCR-SSP            HLA-DQ genotype              12/25/7
  Bastos et al. (2017) \[[@pone.0212329.ref020]\]          Brazil            prospective, multicenter, case-control          66 CD pts and 32 CD/T1DM pts                     not reported (median age 14 years)   RT-PCR             HLA-DQ genotype              16/52/30
  Cabrera et al. (2018) \[[@pone.0212329.ref021]\]         Spain             prospective, single center, case-control        196 CD pts and 206 healthy control               children                             PCR-SSO            HLA-DQ genotype              79/103/14
  Cakir et al. (2014) \[[@pone.0212329.ref022]\]           Turkey            prospective, single center, cross-sectional?    78 CD pts                                        children                             PCR-SSO            HLA-DQ genotype              28/34/14
  Colombe et al. (2015) \[[@pone.0212329.ref037]\]         USA               retrospective, single center, cross-sectional   89 CD pts                                        adults                               PCR-SSP            HLA-DQB1\*0201 allele dose   45/7/37
  Congia et al. (1994) \[[@pone.0212329.ref038]\]          Italy             prospective, single center, case-control        62 CD pts and 89 healthy control                 children and adults                  PCR-SSO            HLA-DQB1\*0201 allele dose   30/31/1
  Eller et al. (2006) \[[@pone.0212329.ref039]\]           Israel            prospective, single center, cross-sectional     175 Beduin kindred                               children and adults                  PCR-SSO            HLA-DQB1\*0201 allele dose   3/3/0
  Greco et al. (1998) \[[@pone.0212329.ref040]\]           Italy             prospective, single center, cross-sectional     145 CD pts                                       children                             PCR-SSO            HLA-DQB1\*02 allele dose     46/84/15
  Gudjonsdottir et al. (2009) \[[@pone.0212329.ref023]\]   Sweden, Norway    prospective, multi-center, cross-sectional      224 CD pts (HLA status was available: 98 pts)    children and adults                  PCR-SSO            HLA-DQ genotype              40/52/6
  Hanif et al. (2017) \[[@pone.0212329.ref024]\]           Pakistan          prospective, single center, observational       12 CD pts                                        children                             PCR                HLA-DQ genotype              5/7/0
  Jores et al. (2007) \[[@pone.0212329.ref012]\]           Italy             retrospective, single center, cross-sectional   187 CD pts                                       children                             PCR-SSO            HLA-DQB1\*0201 allele dose   77/93/17
  Kabatova et al. (2017) \[[@pone.0212329.ref025]\]        Slovakia          retrospective, single center, cross-sectional   258 CD pts (HLA status was available: 217 pts)   children                             PCR-SSP            HLA-DQ genotype              42/97/78
  Karinen et al. (2006) \[[@pone.0212329.ref041]\]         Finland           prospective, single center, cross-sectional     144 CD pts (only siblings from 52 families)      adults                               PCR-SSP            HLA-DQB1\*0201 allele dose   32/103/9
  Mohammed et al. (2014) \[[@pone.0212329.ref042]\]        Egypt             prospective, single center, case-control        31 CD/T1DM pts                                   children and adults                  PCR-SSP            HLA-DQB1\*02 allele dose     16/8/7
  Nenna et al. (2008) \[[@pone.0212329.ref043]\]           Italy             prospective, single center, cross-sectional     124 CD pts                                       children                             PCR-SSP            HLA-DQB1\*02 allele dose     26/85/13
  Ros et al. (2010) \[[@pone.0212329.ref026]\]             Spain             retrospective, single center, cross-sectional   396 CD pts                                       children                             PCR-SSO            HLA-DQ genotype              168/206/17
  Rostami-Nejad et al. (2014) \[[@pone.0212329.ref008]\]   Iran              retrospective, multicenter, case-control        59 CD pts and 151 healthy control                children and adults                  PCR-SSP            HLA-DQ genotype              15/30/14
  Schweiger et al. (2016) \[[@pone.0212329.ref027]\]       Slovenia          prospective, single center, case-control        68 CD pts vs 69 CD/T1DM pts                      children                             PCR-SSO and -SSP   HLA-DQ genotype              41/81/12
  Thomas et al. (2009) \[[@pone.0212329.ref044]\]          UK                retrospective, single center, cross-sectional   384 CD pts (HLA status was available: 360 pts)   adults                               PCR-SSP            HLA-DQB1\*0201 allele dose   71/247/42
  Vegas-Sanchez et al. (2015) \[[@pone.0212329.ref045]\]   Spain             retrospective, single center, cross-sectional   14 CD pts                                        adults                               PCR-SSO            HLA-DQB1\*0201 allele dose   2/7/3
  Vermeulen et al. (2009) \[[@pone.0212329.ref028]\]       The Netherlands   retrospective, single center, cross-sectional   113 CD pts                                       children                             PCR-SSO            HLA-DQ genotype              45/58/10
  Viken et al. (2017) \[[@pone.0212329.ref046]\]           Norway            retrospective, multicenter, case-control        327 CD pts and 215 CD/T1DM pts                   children                             PCR-SSP            HLA-DQB1\*0201 allele dose   141/321/78
  Zubillaga et al. (2002) \[[@pone.0212329.ref047]\]       Spain             prospective, single center, cross-sectional     133 CD pts                                       children                             PCR-SSP            HLA-DQB1\*02 allele dose     63/63/7

CD: celiac disease; PCR-SSP: polymerase chain reaction with sequence-specific primers; PCR-SSO: polymerase chain reaction with sequence-specific oligonucleotide probes, Pts: patients RT-PCR: real-time polymerase chain reaction; T1DM: type 1 diabetes mellitus.

10.1371/journal.pone.0212329.t002

###### Results of meta-analysis.

![](pone.0212329.t002){#pone.0212329.t002g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcomes,\                    Double vs. single dose of HLA-DQB1\*02   Double vs. zero dose of HLA-DQB1\*02                                                                               
  subgroups by age                                                                                                                                                                          
  ----------------------------- ---------------------------------------- ---------------------------------------- ---------------------- ----- -------------------------------------------- ----------------------
  Atrophic vs. non-atrophic     722                                      0.991 (0.406--2.420), *p* = 0.984        11.8%, *p* = 0.338     430   2.626 (1.060--6.505), *p* = 0.037\*          21.3%, *p* = 0.260

  children                      237                                      1.729 (0.319--9.370), *p* = 0.525        71.6%, *p* = 0.061\*   159   1.757 (0.236--13096), *p* = 0.583            0.0%, *p* = 0.542

  adults                        379                                      0.537 (0.175--1.652), *p* = 0.278        0.0%, *p* = 0.682      200   2.534 (0.675--9.507), *p* = 0.168            0.0%, *p* = 0.945

  Marsh 3c vs. Marsh 3a-b       862                                      0.870 (0.514--1.470), *p* = 0.602        39.7%, *p* = 0.127     418   0.822 (0.333--2.032), *p* = 0.671            46.8%, *p* = 0.068\*

  children                      399                                      0.821 (0.401--1.681), *p* = 0.590        0.0%, *p* = 0.397      251   0.975 (0.296--3.208), *p* = 0.967            65.2%, *p* = 0.035\*

  adults                        442                                      0.957 (0.420--2.184), *p* = 0.918        82.4%, *p* = 0.017\*   147   0.753 (0.157--3.599), *p* = 0.722            50.2%, *p* = 0.134

  Classical vs. non-classical   458                                      1.758 (1.148--2.692), *p* = 0.009\*      0.0%, *p* = 0.744      221   1.701 (0.725--3.991), *p* = 0.222            40.7%, *p* = 0.168

  children                      305                                      2.082 (1.189--3.646), *p* = 0.010\*      0.0%, *p* = 0.609      81    3.139 (1.142--8.630), *p* = 0.027\*          0.0%, *p* = 0.747

  Diarrhea vs. non-diarrhea     934                                      1.147 (0.863--1.523), *p* = 0.345        0.0%, *p* = 0.860      421   1.092 (0.655--1.818), *p* = 0.337            0.0%, *p* = 0.856

  children                      616                                      1.143 (0.819--1.593), *p* = 0.432        0.0%, *p* = 0.727      308   1.111 (0.569--2.170), *p* = 0.758            0.0%, *p* = 0.724

  adults                        318                                      1.158 (0.671--1.998), p = 0.599          0.0%, *p* = 1.000      113   1.065 (0.484--2.342), *p* = .0875            0.0%, *p* = 1.000

  Type 1 diabetes mellitus      840                                      0.914 (0.437--1.912), *p* = 0.811        71.8%, *p* = 0.006\*   411   1.169 (0.410--3.331), *p* = 0.770            89.8%, *p*\<0.001\*

  children                      766                                      0.597 (0.218--1.634), *p* = 0.315        79.3%, *p* = 0.008\*   365   0.242 (0.045--1.312), *p* = 0.100            79.4%, *p* = 0.008\*

                                                                         MD (95% CI), *p*-value                   Heterogeneity\               MD (95% CI), *p*-value                       Heterogeneity\
                                                                                                                  (I^2^, chi^2^)                                                            (I^2^, chi^2^)

  Age at diagnosis              512                                      -0.523 (-1.630 to 0.585), *p* = 0.355    28.6%, *p* = 0.231     147   -7.332 (-19.833 to 5.169), *p* = 0.250       71.4%, *p* = 0.015\*

  children                      377                                      -0.303 (-1.156 to 0.551), *p* = 0.487    5.5%, *p* = 0.366      106   -2.026 (-5.824 to 1.771), *p* = 0.296        48.7%, *p* = 0.142

  adults                        133                                      -5.000 (-10.876 to 0.876), *p* = 0.095   0.0%, *p* = 1.000      41    -15.000 (-25.509 to -4.491), *p* = 0.005\*   0.0%, *p* = 1.000
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Asterisks indicate a *p*\<0.05 for OR and MD, and a *p*\<0.10 for heterogeneity tested with chi^2^-test. CI: confidence interval; OR: odds ratio; MD: mean difference.

Clinical presentation {#sec013}
---------------------

Five studies \[[@pone.0212329.ref022], [@pone.0212329.ref023], [@pone.0212329.ref038], [@pone.0212329.ref043], [@pone.0212329.ref047]\] were included in the comparison of classical vs. non-classical CD regarding double vs. single dose of HLA-DQB1\*02; of them, four \[[@pone.0212329.ref022], [@pone.0212329.ref023], [@pone.0212329.ref038], [@pone.0212329.ref043]\] were included in the analysis regarding double vs. zero dose of HLA-DQB1\*02. Patients with a double dose of HLA-DQB1\*02 had classical CD more frequently, compared to those having a single dose of the allele (OR = 1.758, CI: 1.148 to 2.692, *p* = 0.009) in a homogeneous dataset (I^2^ = 0.0%, *p* = 0.744) ([Fig 2](#pone.0212329.g002){ref-type="fig"}). The difference was more prominent in the subgroup of children (OR = 2.082, CI: 1.189 to 3.646, *p* = 0.010) in a homogeneous dataset (I^2^ = 0.0%, *p* = 0.609) ([Fig 2](#pone.0212329.g002){ref-type="fig"}). In the analysis of a double dose of HLA-DQB1\*02 vs. a zero dose of the allele, we detected a significant gene dose effect only if children were included in the analysis (OR = 3.139, CI: 1.142 to 8.630, *p* = 0.027) in a homogeneous dataset (I^2^ = 0.0%, *p* = 0.747) ([Fig 3](#pone.0212329.g003){ref-type="fig"}). Setting up the subgroup of children reduced the heterogeneity from 40.7% to 0.0% ([Fig 3](#pone.0212329.g003){ref-type="fig"}).

![Odds ratios of classical presentation of CD at diagnosis with double dose vs. single dose of HLA-DQB1\*02.\
Patients with a double dose of HLA-DQB1\*02 had classical CD more frequently compared to those having a single dose. This association was more prominent in children. Heterogeneity of the groups overall: I^2^ = 0.0%, *p* = 0.744; heterogeneity of the subgroup of children: I^2^ = 0.0%, *p* = 0.609. CI: confidence interval.](pone.0212329.g002){#pone.0212329.g002}

![Odds ratios of classical presentation of CD at diagnosis with double dose vs. zero dose of HLA-DQB1\*02.\
A significant gene dose effect was detected in the subgroup of children. Heterogeneity of the groups overall: I^2^ = 40.7%, *p* = 0.168; heterogeneity of the subgroup of children: I^2^ = 0.0%, *p* = 0.747. CI: confidence interval.](pone.0212329.g003){#pone.0212329.g003}

Five studies \[[@pone.0212329.ref024], [@pone.0212329.ref026], [@pone.0212329.ref028], [@pone.0212329.ref040], [@pone.0212329.ref044]\] reported on the presence of diarrhea at diagnosis, all were included in the analysis of double vs. single dose of HLA-DQB1\*02 and that of double vs. zero dose of the allele, as well. We failed to detect a significant gene dose effect, nor in the subgroups of children and adults in a homogeneous dataset (I^2^ = 0.0%) ([Table 2](#pone.0212329.t002){ref-type="table"}, [S1](#pone.0212329.s004){ref-type="supplementary-material"} and [S2](#pone.0212329.s005){ref-type="supplementary-material"} Figs).

Age at diagnosis {#sec014}
----------------

Four \[[@pone.0212329.ref028], [@pone.0212329.ref036], [@pone.0212329.ref041], [@pone.0212329.ref043]\] and five studies \[[@pone.0212329.ref028], [@pone.0212329.ref036], [@pone.0212329.ref041], [@pone.0212329.ref043], [@pone.0212329.ref047]\] were included in the comparison of double vs. zero dose of HLA-DQB1\*02 and double vs. single dose of the allele concerning age at diagnosis, respectively. Patients with a double dose of HLA-DQB1\*02 were similar in age at diagnosis, compared to their counterparts with single and zero doses of the allele (MD: -0.523, CI: -1.630 to 0.585, *p* = 0.355; I^2^ = 28.60% and MD: -7.332, CI: -19.833 to 5.169, *p* = 0.250; I^2^ = 71.4% respectively) ([S3](#pone.0212329.s006){ref-type="supplementary-material"} and [S4](#pone.0212329.s007){ref-type="supplementary-material"} Figs). In the subgroup of children, heterogeneity was considerably reduced ([Table 2](#pone.0212329.t002){ref-type="table"}).

Histology at diagnosis {#sec015}
----------------------

Eight studies \[[@pone.0212329.ref008], [@pone.0212329.ref019], [@pone.0212329.ref025], [@pone.0212329.ref037], [@pone.0212329.ref042]--[@pone.0212329.ref045]\] were eligible for inclusion in the comparison of atrophic vs. non-atrophic histology, all were included in the analysis of double vs. single dose of HLA-DQB1\*02 and that of double vs. zero dose of the allele, as well. Villous atrophy at diagnosis was not more frequent in patients with a double dose of HLA-DQB1\*02, as compared to a single dose of the allele (OR = 0.991, CI: 0.406 to 2.420, *p* = 0.984) in a homogeneous dataset (I^2^ = 11.8%, *p* = 0.338) ([Fig 4](#pone.0212329.g004){ref-type="fig"}). In contrast, patients with a double dose of the allele were more likely to have villous atrophy at diagnosis than those with a zero dose of the allele (OR = 2.626, CI: 1.060 to 6.505, *p* = 0.037) ([Fig 5](#pone.0212329.g005){ref-type="fig"}). The subgroup analysis of children and adults did not result in significances across groups (Figs [4](#pone.0212329.g004){ref-type="fig"} and [5](#pone.0212329.g005){ref-type="fig"}, [Table 2](#pone.0212329.t002){ref-type="table"}).

![Odds ratios of atrophic histology at diagnosis with double dose vs. single dose of HLA-DQB1\*02.\
We failed to detect a significant gene dose effect regarding diagnostic histology. Heterogeneity of the groups overall: I^2^ = 11.8%, *p* = 0.338; heterogeneity of the subgroup of adults: I^2^ = 0.0%, *p* = 0.682; heterogeneity of the subgroup of children: I^2^ = 71.6%, p = 0.061. CI: confidence interval.](pone.0212329.g004){#pone.0212329.g004}

![Odds ratios of atrophic histology at diagnosis with double dose vs. zero dose of HLA-DQB1\*02.\
Patients with a double dose of the allele were more likely to have villous atrophy at diagnosis than those with a single dose of the allele. Heterogeneity of the groups overall: I^2^ = 21.3%, *p* = 0.260; heterogeneity of the subgroup of adults: I^2^ = 0.0%, *p* = 0.945; heterogeneity of the subgroup of children: I^2^ = 0.0%, *p* = 0.542. CI: confidence interval.](pone.0212329.g005){#pone.0212329.g005}

Regarding the severity of villous atrophy, seven \[[@pone.0212329.ref012], [@pone.0212329.ref024], [@pone.0212329.ref025], [@pone.0212329.ref041]--[@pone.0212329.ref044]\] and eight studies \[[@pone.0212329.ref012], [@pone.0212329.ref024], [@pone.0212329.ref025], [@pone.0212329.ref041]--[@pone.0212329.ref045]\] were eligible for inclusion in the analysis of double vs. single dose of HLA-DQB1\*02 and that of double vs. zero dose of the allele. Marsh 3c at diagnosis was not more frequent in patients with a double dose of HLA-DQB1\*02, as compared to single and zero doses of the allele (OR = 0.870, CI: 0.514 to 1.470, *p* = 0.602 \[I^2^ = 39.7%, *p* = 0.127\] and OR = 0.822, CI: 0.333 to 2.032, *p* = 0.671 \[I^2^ = 46.8%, *p* = 0.068\], respectively). These remained unchanged in the subgroups of children and adults ([S5](#pone.0212329.s008){ref-type="supplementary-material"} and [S6](#pone.0212329.s009){ref-type="supplementary-material"} Figs, [Table 2](#pone.0212329.t002){ref-type="table"}).

Type 1 diabetes mellitus {#sec016}
------------------------

Five \[[@pone.0212329.ref020], [@pone.0212329.ref021], [@pone.0212329.ref027], [@pone.0212329.ref039], [@pone.0212329.ref046]\] studies were included in the analysis of double vs. single dose of HLA-DQB1\*02; of them, four \[[@pone.0212329.ref020], [@pone.0212329.ref021], [@pone.0212329.ref027], [@pone.0212329.ref046]\] were eligible for inclusion in the analysis of double vs. zero dose of the allele. Analyses revealed no significant gene dose effect concerning the coexistence of type 1 diabetes mellitus and CD, which remained unchanged in the subgroups of children and adults. All analyses suffered from significant heterogeneity ([S7](#pone.0212329.s010){ref-type="supplementary-material"} and [S8](#pone.0212329.s011){ref-type="supplementary-material"} Figs, [Table 2](#pone.0212329.t002){ref-type="table"}).

Other patient and disease characteristics {#sec017}
-----------------------------------------

There were several reports on the association between HLA-DQ2 gene dose effect and the clinical phenotype of CD (age at onset, anemia, serology, autoimmunity, body mass index, osteoporosis, oral manifestations, complicated CD, and dermatitis herpetiformis). Data reported were insufficient for quantitative synthesis. We report the studies and the direction of associations with HLA-DQ gene dose in [Table 3](#pone.0212329.t003){ref-type="table"}.

10.1371/journal.pone.0212329.t003

###### Summary of studies reporting on gene dose effect.

![](pone.0212329.t003){#pone.0212329.t003g}

  Characteristics                        Association between HLA-DQ2 gene dose and the clinical phenotype                                                                                                                                                                                                                                                                                                                                                                                                                                          
  -------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------
  Clinical presentation                  \[[@pone.0212329.ref038], [@pone.0212329.ref041], [@pone.0212329.ref043], [@pone.0212329.ref047], [@pone.0212329.ref051], [@pone.0212329.ref066], [@pone.0212329.ref069], [@pone.0212329.ref079]\]   \[[@pone.0212329.ref007], [@pone.0212329.ref012], [@pone.0212329.ref023], [@pone.0212329.ref026], [@pone.0212329.ref028], [@pone.0212329.ref036], [@pone.0212329.ref040], [@pone.0212329.ref044], [@pone.0212329.ref061], [@pone.0212329.ref071], [@pone.0212329.ref072], [@pone.0212329.ref074]\]   
  Age at onset                           \[[@pone.0212329.ref047]\]                                                                                                                                                                           \[[@pone.0212329.ref026], [@pone.0212329.ref040], [@pone.0212329.ref045], [@pone.0212329.ref053], [@pone.0212329.ref071], [@pone.0212329.ref073], [@pone.0212329.ref075]--[@pone.0212329.ref077]\]                                                                                                   
  Age at diagnosis                       \[[@pone.0212329.ref038], [@pone.0212329.ref041], [@pone.0212329.ref047], [@pone.0212329.ref066]\]                                                                                                   \[[@pone.0212329.ref028], [@pone.0212329.ref036], [@pone.0212329.ref040], [@pone.0212329.ref044], [@pone.0212329.ref071], [@pone.0212329.ref072]\]                                                                                                                                                   \[[@pone.0212329.ref013], [@pone.0212329.ref068]\]
  Histology at diagnosis                 \[[@pone.0212329.ref012], [@pone.0212329.ref037], [@pone.0212329.ref041], [@pone.0212329.ref043], [@pone.0212329.ref078]\]                                                                           \[[@pone.0212329.ref007], [@pone.0212329.ref028], [@pone.0212329.ref036], [@pone.0212329.ref044], [@pone.0212329.ref053], [@pone.0212329.ref069], [@pone.0212329.ref071]\]                                                                                                                           
  Anemia                                 \[[@pone.0212329.ref041]\]                                                                                                                                                                           \[[@pone.0212329.ref026], [@pone.0212329.ref036], [@pone.0212329.ref040], [@pone.0212329.ref043], [@pone.0212329.ref044]\]                                                                                                                                                                           
  Serology                               \[[@pone.0212329.ref007], [@pone.0212329.ref042], [@pone.0212329.ref043], [@pone.0212329.ref067], [@pone.0212329.ref069], [@pone.0212329.ref070]\]                                                   \[[@pone.0212329.ref036], [@pone.0212329.ref044], [@pone.0212329.ref048], [@pone.0212329.ref059], [@pone.0212329.ref065], [@pone.0212329.ref071], [@pone.0212329.ref078]\]                                                                                                                           
  Autoimmunity                           \[[@pone.0212329.ref027], [@pone.0212329.ref039], [@pone.0212329.ref062]\]                                                                                                                           \[[@pone.0212329.ref064]\]                                                                                                                                                                                                                                                                           \[[@pone.0212329.ref046], [@pone.0212329.ref054]\]
  Body mass index                                                                                                                                                                                                                             \[[@pone.0212329.ref026], [@pone.0212329.ref044]\]                                                                                                                                                                                                                                                   
  Osteoporosis                                                                                                                                                                                                                                \[[@pone.0212329.ref044]\]                                                                                                                                                                                                                                                                           
  Oral manifestations (DED, RAS)         \[[@pone.0212329.ref055], [@pone.0212329.ref063]\]                                                                                                                                                   \[[@pone.0212329.ref044]\]                                                                                                                                                                                                                                                                           
  Complicated disease (RCD, EATL, SBC)   \[[@pone.0212329.ref014], [@pone.0212329.ref049], [@pone.0212329.ref050], [@pone.0212329.ref064]\]                                                                                                   \[[@pone.0212329.ref058]\]                                                                                                                                                                                                                                                                           
  Dermatitis herpetiformis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         \[[@pone.0212329.ref057]\]

DED: dental enamel defect; EATL: enteropathy-associated T-cell lymphoma; RAS: recurrent aphthous stomatitis; RCD: refractory celiac disease; SBC: small bowel carcinoma.

Publication bias {#sec018}
----------------

Although funnel plots seem symmetric, the low number of studies raised concerns about an uncertain assessment of symmetry ([S3 Appendix](#pone.0212329.s014){ref-type="supplementary-material"}).

Sensitivity analysis {#sec019}
--------------------

When we omitted studies one-by-one, there was no change in the direction of the main association, except for two outcomes. Omitting Zubillaga et al. from the analysis on classic vs. non-classic clinical presentation resulted in the loss of statistical significance in the comparison of double vs. single dose. Omitting Vermeulen et al. from the analysis on age at diagnosis, resulted in a significant gene dose effect (MD = -0.248, CI: -0.464 to -0.032, *p* = 0.024) in the comparison of double vs. single dose.

Risk of bias assessment {#sec020}
-----------------------

Results of risk of bias assessment are presented in [Fig 6](#pone.0212329.g006){ref-type="fig"}. Ten out of 24 studies (41.7%) aimed to analyze gene dose effect primarily. Twenty-two out of 24 (91.7%) and 18 out of 24 (75.0%) studies used a low-risk classification for diagnosing CD and rating diagnostic histology, respectively. However, the average CD population was clearly represented only in 62.5% of the studies included. Appropriate blinding was applied in only one study (4.2%).

![Summary of risk of bias in individual studies included in meta-analysis.\
Green, red, and blue icons represent low, high, and uncertain risk of bias. Definitions of items are provided in [S1 Table](#pone.0212329.s001){ref-type="supplementary-material"}.](pone.0212329.g006){#pone.0212329.g006}

Discussion {#sec021}
==========

We aimed to review the current knowledge about the influence of HLA-DQB1\*02 gene dose on the phenotype of celiac disease in our study.

Although reasonable molecular mechanisms have been proposed by *in vitro* experiments \[[@pone.0212329.ref005], [@pone.0212329.ref006]\], gene dose effect seemed to influence only the clinical phenotype defined by Oslo criteria and histology. Patients with a double dose of HLA-DQB1\*02 exhibited more often classical phenotype and villous atrophy, as compared to those with a single dose of the allele, whereas no evidence of gene dose effect was collected on diarrhea, age at diagnosis, the severity of villous atrophy, and the frequency of type 1 diabetes mellitus ([Table 2](#pone.0212329.t002){ref-type="table"}).

Lack of clinically significant gene dose effect is also supported by experimental results, as well: (1) an equal magnitude of specific T-cell responses characterizes homo- and heterozygotes, (2) the amount of DQA1\*05 and DQB1\*02 mRNS in heterozygotes exceeded the expected 50% of that measured in homozygotes \[[@pone.0212329.ref080]\]. Other factors should be taken into consideration, e.g., complementing HLA risk stratification with ten non-HLA loci changed the allocation of 10% of study population from the moderate- to the high-risk group \[[@pone.0212329.ref081]\]. The effect of non-HLA loci may outweigh that of HLA. In addition, non-genetic (environmental) factors appear to contribute to CD phenotype \[[@pone.0212329.ref023], [@pone.0212329.ref028], [@pone.0212329.ref040]\].

Concerning comorbid conditions, data allowed us to perform analysis only on type 1 diabetes mellitus, which is the most frequent co-existing immune-mediated disorder in CD. We failed to observe a significant gene dose effect in the frequency of type 1 diabetes mellitus. This corroborates with previous studies confirming that the combined occurence of DQ2 and DQ8 is high in patients with both CD and type 1 diabetes mellitus \[[@pone.0212329.ref027], [@pone.0212329.ref046], [@pone.0212329.ref054]\].

Although we were unable to meta-analyze other disease complications due to discrepancies in reporting, the importance of HLA-DQ2 gene dose might be highlighted by these studies ([Table 3](#pone.0212329.t003){ref-type="table"}). HLA status appears to be important in the development of malignant complications. Lymphomatous complications were more frequent in patients with a double dose of HLA-DQ2 in a study \[[@pone.0212329.ref064]\]. In a prospective study conducted by Al-Toma et al., HLA-DQ2.5 homozygosity was associated with serious CD complications, namely, type 2 refractory celiac disease and enteropathy-associated T-cell lymphoma \[[@pone.0212329.ref014]\]. Prevalence of DQ2 homozygosity was significantly higher in patients with a complicated disease (i.e., patients with type 1 and type 2 refractory CD, EATL, or SBC), as compared to those with non-complicated CD in a retrospective Italian and a multicentre study \[[@pone.0212329.ref049], [@pone.0212329.ref050]\]. However, it is noteworthy that data of Howell et al. did not confirm these observations \[[@pone.0212329.ref058]\]. Further studies aiming to resolve these controversies are awaited to test whether determining HLA gene dose is appropriate for risk stratification for severe complications.

Strengths and limitations {#sec022}
-------------------------

To date, no meta-analyses have investigated HLA-DQB1\*02 gene dose effect in CD. Our main strength is the transparent and comprehensive search and the rigorous selection process; however, we must acknowledge that the evidence is limited due to a number of reasons.

We did not contact the original authors of the included or excluded papers to acquire further information; only published material was used to preserve reproducibility.

Data on the clinical phenotype of celiac disease were collected from patients' files retrospectively. Regarding HLA status, HLA-typing was performed (1) at the time of enrolment to the study (at or after the diagnosis of celiac disease) or (2) before enrolment (retrospectively collected from charts). In relation to the outcomes, both ways are retrospective. However, HLA is a genetic marker, an unchangeable feature of the patients. Therefore, in our opinion, timing of HLA-typing does not affect data quality.

Design of the studies included were (1) controlled studies including celiac and non-celiac subjects (case-control or cross-sectional studies) or (2) uncontrolled case series reports of celiac patients. In this meta-analysis, data on celiac patients were desirable, exclusively (while the non-celiac groups were irrelevant for us). As a consequence, there were studies included not aiming to analyze gene dose effect, as a primary objective, which may limit the data reported from the studies.

The number of eligible studies was low, not allowing us to draw reliable conclusions from the symmetry of the funnel plots to assess small-study effect ([S3 Appendix](#pone.0212329.s014){ref-type="supplementary-material"}).

Relevant clinical questions as to whether gene dose effects anemia, complications of CD, or serology have not been meta-analyzed due to incoherent data reporting across studies ([S2 Table](#pone.0212329.s002){ref-type="supplementary-material"}).

As only nine studies typed HLA-DQB1\*0201 \[[@pone.0212329.ref012], [@pone.0212329.ref036]--[@pone.0212329.ref039], [@pone.0212329.ref041], [@pone.0212329.ref044]--[@pone.0212329.ref046]\] (the rest of them typed DQB1\*02 allele \[[@pone.0212329.ref040], [@pone.0212329.ref042], [@pone.0212329.ref043], [@pone.0212329.ref047]\]), our conclusion is not generalizable to the role of HLA-DQB1\*0201 which may be of greater clinical importance. DQB1\*02 allele dose was calculated from DQ2 haplotype-based HLA risk stratification systems in eleven studies \[[@pone.0212329.ref008], [@pone.0212329.ref019]--[@pone.0212329.ref028]\].

Self-reported clinical symptoms (e.g., bloating, diarrhea, and abdominal discomfort) are difficult to quantify objectively. To minimize the distortion, we used the widely accepted Oslo classification (i.e., dichotomization of patients into classical \[with malabsorption\] and non-classical \[without malabsorption\] phenotypes) \[[@pone.0212329.ref016]\].

Some analyses suffer from statistical heterogeneity ([Table 2](#pone.0212329.t002){ref-type="table"}) which can be explained by methodological heterogeneity (i.e., histological assessment, HLA-typing, inclusion and exclusion of subjects) and clinical heterogeneity (i.e., geography, diverse environmental factors \[e.g., timing of gluten introduction\], and genetics \[i.e., HLA and non-HLA loci\]). A part of heterogeneity may originate from the age of participants: heterogeneity reduced when analyzing data from children and adults separately in some analysis, while persisted in others ([Table 2](#pone.0212329.t002){ref-type="table"}).

Conclusion {#sec023}
==========

Implications for clinical practice {#sec024}
----------------------------------

Our results suggest a significant gene dose effect regarding clinical presentation: classical clinical presentation and villous atrophy are more frequent in patients with a double dose of HLA-DQB1. We were unable to prove a similar effect in terms of diarrhea at diagnosis, age at diagnosis, the degree of atrophy, and type 1 diabetes mellitus. Recent guidelines do not require HLA-typing to set up the diagnosis of CD apart from pediatric cases diagnosed without intestinal biopsy. The role of it is mainly restricted to the exclusion of CD \[[@pone.0212329.ref082], [@pone.0212329.ref083]\]. Patients with high-risk HLA status may be at higher risk of severe disease course, raising concerns about the need for a stricter gluten-free diet and follow-up. However, these results should be treated with caution due to the limitations of the data available for our study.

Implications for research {#sec025}
-------------------------

Studies validating our results and investigating the association between gene dose effect and disease complications (e.g., malignant tumors \[EATL, SBC\], autoimmune disorders, and RCD) are awaited.
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